Literature DB >> 23787551

Severe lupus nephritis: the predictive value of a ≥ 50% reduction in proteinuria at 6 months.

Stephen M Korbet1, Edmund J Lewis.   

Abstract

BACKGROUND: A complete remission (CR) in severe lupus nephritis (SLN) is associated with a favorable long-term outcome. Initial therapy may be up to 6 months, but many patients do not achieve a CR until after 12 months. We assess the value of a ≥50% reduction in proteinuria (UPro) at 6 months in predicting the outcome in SLN patients.
METHODS: We evaluated the 86 adult patients in the prospective, controlled trial of plasmapheresis (PP) in SLN (NEJM 1992). Patients with a CR (n = 12), end-stage renal disease (ESRD) or death (n = 13) at ≤6 months were excluded. The remaining 61 patients were categorized into two groups based on having attained a ≥50% reduction in UPro at 6 months: (yes) 34 patients and (no) 27 patients. The long-term outcomes were compared. A CR was defined by a serum creatinine (SCr) of ≤1.4 mg/dL and UPro of ≤0.33 g/day.
RESULTS: Baseline features were similar, but the UPro was higher (7.1 ± 3.6 versus 4.6 ± 3.2, P 0.002) in the group with a ≥50% reduction in UPro at 6 months. At follow-up, a CR was attained in 56% of patients with a ≥50% reduction in UPro at 6 months compared with 22% (P = 0.009) in the group without. The 15-year renal survival (71 versus 25%, P = 0.005) and patient survival without ESRD (66 versus 18%, P = 0.004) was greatest in the patients with a ≥50% reduction in UPro at 6 months.
CONCLUSION: A ≥50% reduction in UPro at 6 months predicts a favorable outcome in SLN.

Entities:  

Keywords:  proteinuria; remission; severe lupus nephritis

Mesh:

Substances:

Year:  2013        PMID: 23787551     DOI: 10.1093/ndt/gft201

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  Treatment of severe lupus nephritis: the new horizon.

Authors:  Tak Mao Chan
Journal:  Nat Rev Nephrol       Date:  2014-11-25       Impact factor: 28.314

2.  Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?

Authors:  Cátia Cunha; Suceena Alexander; Damien Ashby; Janet Lee; Gary Chusney; Tom D Cairns; Liz Lightstone
Journal:  Nephrol Dial Transplant       Date:  2018-09-01       Impact factor: 5.992

3.  A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial.

Authors:  Farah Tamirou; Bernard R Lauwerys; Maria Dall'Era; Meggan Mackay; Brad Rovin; Ricard Cervera; Frédéric A Houssiau
Journal:  Lupus Sci Med       Date:  2015-11-12

4.  Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV.

Authors:  Hironari Hanaoka; Hidehiro Yamada; Tomofumi Kiyokawa; Harunobu Iida; Takeshi Suzuki; Yoshioki Yamasaki; Seido Ooka; Hiroko Nagafuchi; Takahiro Okazaki; Daisuke Ichikawa; Sayuri Shirai; Yugo Shibagaki; Junki Koike; Shoichi Ozaki
Journal:  Arthritis Res Ther       Date:  2017-01-13       Impact factor: 5.156

5.  Clinical predictors of proteinuric remission following an LN flare - evidence from the UK JSLE cohort study.

Authors:  Eve M D Smith; Peng Yin; Andrea L Jorgensen; Michael W Beresford
Journal:  Pediatr Rheumatol Online J       Date:  2018-02-21       Impact factor: 3.054

6.  Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis.

Authors:  Vinicius Domingues; Benjamin A Levinson; Nicole Bornkamp; Judith D Goldberg; Jill Buyon; H Michael Belmont
Journal:  Lupus Sci Med       Date:  2018-09-04

Review 7.  Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?

Authors:  Ioannis Parodis; Farah Tamirou; Frédéric A Houssiau
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-02-11       Impact factor: 4.291

8.  Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial.

Authors:  Zhaohui Zheng; Haitao Zhang; Xiaomei Peng; Chun Zhang; Changying Xing; Gang Xu; Ping Fu; Zhaohui Ni; Jianghua Chen; Zhonggao Xu; Ming-Hui Zhao; Shaomei Li; Xiangyang Huang; Lining Miao; Xiaonong Chen; Bicheng Liu; Yongcheng He; Jing Li; Lijun Liu; Haishan Kadeerbai; Zhangsuo Liu; Zhihong Liu
Journal:  JAMA Netw Open       Date:  2022-03-01

9.  Characteristics of azathioprine use and cessation in a longitudinal lupus cohort.

Authors:  Lucy Croyle; Alberta Hoi; Eric F Morand
Journal:  Lupus Sci Med       Date:  2015-08-20

Review 10.  Prediction of prognosis and renal outcome in lupus nephritis.

Authors:  Ioannis Parodis; Farah Tamirou; Frédéric A Houssiau
Journal:  Lupus Sci Med       Date:  2020-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.